Search results
30 mar 2022 · Alzheimer’s disease (AD) is an irreversible brain disorder associated with slow, progressive loss of brain functions mostly in older people. The disease processes start years before the symptoms are manifested at which point most therapies may not be as effective.
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
The physiological structure of the brain and neurons in (a)...
- The biological pathways of Alzheimer disease: a review
Alzheimer disease is a progressive neurodegenerative...
- Pathophysiology of Alzheimer's Disease - PubMed
Recent biomarker and neuroimaging research has revealed how...
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
8 gru 2020 · The physiological structure of the brain and neurons in (a) healthy brain and (b) Alzheimer’s disease (AD) brain. At present, there are around 50 million AD patients worldwide and this number is projected to double every 5 years and will increase to reach 152 million by 2050.
16 gru 2020 · Alzheimer disease is a progressive neurodegenerative disorder, mainly affecting older people, which severely impairs patients' quality of life. In the recent years, the number of affected individuals has seen a rapid increase. It is estimated that up to 107 million subjects will be affected by 2050 worldwide.
30 sie 2021 · Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology.
Recent biomarker and neuroimaging research has revealed how the pathophysiology of AD may lead to symptoms, and as the pathophysiology of AD gains clarity, more potential treatments are emerging that aim to modify the disease and relieve its burden.
23 mar 2018 · Changes in these physiological processes are present in several conditions, including frontotemporal dementia, amyotrophic lateral sclerosis, Alzheimer disease and the parkinsonian plus...
The differences between sporadic Alzheimer’s disease (AD) cases could be, in part, explained by the heterogeneity of neuropathological aspects, based on the multiplicity of the compositions of amyloid plaques, the patterns of tau pathology distribution, and the variability of neuropathological comorbidities.
